Sex: U
Vaccine: COVID19
Symptoms: Body temperature, Headache, Malaise, Nausea, Pyrexia
Clinical narrative: Mild malaise/feeling sick and no interference with activity; Mild fever (100.4 to 101.2 °F); Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Headache and no interference with activity; Moderate injection site redness; Mild injection site swelling; Mild injection site pain and no interference with activity/ Mild injection site tenderness (tender to touch); This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Mild malaise/feeling sick and no interference with activity), PYREXIA (Mild fever (100.4 to 101.2 °F)), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and HEADACHE (Headache and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Mild malaise/feeling sick and no interference with activity), PYREXIA (Mild fever (100.4 to 101.2 °F)), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), HEADACHE (Headache and no interference with activity), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling) and VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ Mild injection site tenderness (tender to touch)). At the time of the report, MALAISE (Mild malaise/feeling sick and no interference with activity), PYREXIA (Mild fever (100.4 to 101.2 °F)), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), HEADACHE (Headache and no interference with activity), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling) and VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ Mild injection site tenderness (tender to touch)) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 100.4 to 101.2 Degree F, Mild fever..     The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.        Concomitant medication was not provided. During the 2 days after COVID-19 vaccination, i.e., 21-Dec-2023 and 22-Dec-2023, patient experienced mild injection site pain and no interference with activity, mild injection site tenderness (tender to touch), moderate injection site redness, mild injection site swelling, mild fever, mild malaise/feeling sick and no interference with activity, mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting and headache and no interference with activity. Treatment information was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:Master case